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THE USE OF HYPOALLERGENIC MIXTURES
IN CHILDREN WITH SIGNS OF ATOPY
Abstract. Introduction. Studies are indicative that about a quarter of infants
in Ukraine have atopic manifestations. If the breastfeeding is impossible,
hypoallergenic mixtures should be used. The arm of the research. To
establish clinico-paraclinical efficacy of hypoallergenic mixtures TM
“Humana Ha” in infants with clinical manifestations of atopic abnormality
of constitution. Methods. 27 children aged from 2 to 12 months with the
symptoms of atopic dermatitis and 25 infants who were fed on formula and
had the usual signs of wheezing syndrome underwent complex examination.
Results. In the Ist clinical group among patients with mild forms of eczema
(11,1%) score on EASI scale decreased from 28,8 ± 2,1 to score 12,2 ± 1,8
score (P <0,05). The using mixture “Humana-HA” was led to a decrease in
absolute risk register high concentration of IL-4 in serum by 20,9%, relative
risk reduction – 23,5% (95% CI 15,5-33,1), and the minimum number of
patients which should be treatment to get one positive result was 4,2 (95% CI
1,2-10,4). Conclusions. The using of partially hydrolyzed mixture “Humana-
HA” in infants with signs of atopic dermatitis significantly improves the flow
of mild and moderate forms. Application of partial protein hydrolyzate
”Humana-HA” in the diet of infants with atopic dermatitis reduces the
content of immunoglobulin E and interleukin-4 in serum.
Key words: children, food allergy,
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hydrolyzate.
Introduction
Continuous growth of allergic disease in young
children today resulted in the actuality and importance
of this disease’s prevention [1,3]. The studies which
were conducted over the last 10 years showed that
about a quarter of infants in Ukraine have atopic
manifestations [2]. However, almost in one-third of
the population allergic diseases are formed only due to
the influence of environmental incentives [4,5] which
for infants primarily serve food allergens, including
cow’s milk proteins (CMP). Allergy to CMP is
detected in 0,3% of infants and 7,5% of young
children [6]. Primary prevention of food allergy to
cow’s milk protein allergy is the prevention of the
formation of a child’s phenotype in the future.
Modern approaches to non-drug measures for
primary prevention of allergies in children predict
preservation of breastfeeding for all children without
exception [7]. When the breastfeeding is impossible it
should be used hypoallergenic alternatives [8,9,10].
According to the requirements of the European
Union pediatricians, gastroenterologists, nutritionists
hypoallergenic mixture should be characterized by
good tolerability in 90% of children suffering from
allergies to CMP, contain low residual amount of
antigens, to meet rates of growth and development of
children. Hypoallergenic mixture TM “Humana HA”
satisfies these requirements. These products have
therapeutic and prophylactic properties and can be
used to prevent and treat food allergies of mild and
moderate severity.
The aim of the research
To establish clinico-paraclinical efficacy of
hypoallergenic mixtures TM “Humana Ha” in infants
with clinical manifestations of atopic abnormality
constitution.
Material and Methods
To achieve this aim a dynamic integrated clinico-
immunological surveillance examination of 27
children aged from 2 to 12 months with the
symptoms of atopic dermatitis (I clinical group) has
been carried out. 25 infants who were fed on formula
and had the usual signs of wheezing syndrome
constited a referent group. All children were
examined in the department for children under 1 year
of Regional Children’s Clinical Hospital, Chernivtsi,
and the average length of the dynamic supervision
was 3,2 ± 0,06 months. As to the main clinical
parameters groups were collated.
Severity of atopic dermatitis symptoms was
assessed on an EASI scale [11] according to the
clinical trials program of the hypoallergenic baby
food mixtures TM “Humana HA”. Criteria for
evaluating of the effectiveness of nutrition were:
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indicators of therapeutic efficacy (recurrent
symptoms of atopic dermatitis (AD)) and changes of
immunological research indicators. The
manifestations of AD in children were determined in
a rash of different localization and character, dryness,
redness, swelling, itching of the skin. In addition,
cracks, scales, crusts on the skin were registered.
Along with clinical observations it was conducted
a complex immunological blood test II - III levels,
including content of interleukin-4 (IL-4) and
immunoglobulin E (Ig E) in serum.
The work was done due to randomized
comparative study in parallel groups by an
“experiment-control” method. The results were
analyzed by methods of variational statistics using
statistical software StatSoft Statistica v5.0. and clinical
epidemiology. The effectiveness of the treatment was
evaluated taking into account a decrease of the
absolute risk (DAR), relative (DRR) risk, as well as
the minimum number of patients (MNP), which
should be treated to get one positive result. The critical
significance level “p” when checking statistical
hypotheses in this study received equal 0,05.
Discussion of the study results
Against a background of using hypoallergenic
mixture TM “Humana HA” its good tolerability, a
significant improvement of appetite and sleep was
observed in all children. In 11 children (40,7%) with
the symptoms of AD during using the hypoallergenic
mix “Humana HA-2” a significant positive clinical
dynamics was observed: all symptoms since the 3rd
day, gradually decreased and completely disappeared
before the 14th day of observation. In 5 children
(18,5%) with AD during using the mixture maximal
effect was observed in 3 - 5 days. Rash, redness,
itching were gone, but dry skin, single rashes various
locations were kept to the end of the study. New skin
manifestations in these children were not observed.
According to the utilized scale for evaluation of
the area and atopic dermatitis severity (EASI),
significant improvements against a background of
feading of hypoallergenic infants have occured.
Thus, in the I clinical group among patients with
mild forms of eczema (11,1%) score on this scale
decreased from 28,8 ± 2,1 to 12,2 ± 1,8 (P<0,05). In
the subgroups of children with moderate (66,6%) and
severe course of the (22,2%) disease the same
changes were: 50,1 ± 1,9 and 27,6 ± 1,7 in the first
case and 65,6 ± 1.5 versus 39,3 ± 1,4 ball - in the
second (P<0,05). Transformation to lighter variants
of atopic dermatitis clinical course in 66,6% of
children with mild and moderate symptoms and only
33,3% - with severe, which is underlining higher
efficacy of hypoallergenic products under study in
the diet of mild and moderate forms of atopic
diseases has been marked.
According to the literature [12,13], allergic
inflammation is accompanied by some changes in the
immune status of patients, such as increased number
of T - lymphocytes the function of which is
associated with a helper, a decrease of T - cell
subpopulations, whose function is associated with
suppressor. Enhanced response of T-helper cells is
accompanied by increased production of interleukin-
4, under which there is hypersecretion of total
immunoglobulin E - an objective marker of atopy.
Due to increased concentrations of serum total
immunoglobulin E and the role of interleukin-4 in
atopic diseases it was expedient to determine the
parameters of the humoral immune system in
children of the group under observation (Table).
As can be seen from the data, significant
differences as to the content of IL-4 in the serum
were not found between groups of patients, although
the content of IgE differences was statistically
significant. At the same time, among patients who
did not receive hypoallergenic mix “Humana HA”
significantly greater part of children was marked in
the serum which the content of IL-4 was determined
more than 40 pg / ml, regarding to children who were
bottle-fed with hypoallergenic blend (33,3 ± 6,8%
versus 11,5 ± 5,1%, p <0,05). It should be noted that
the using mixture “Humana-HA” was led to a
decrease in absolute risk register high concentration
of IL-4 in serum by 20,9%, relative risk reduction –
23,5% (95% CI 15,5-33,1), and the minimum
number of patients which should be treatment to get
one positive result was 4,2 (95% CI 1,2-10,4).
Thus, the results of clinico-immunological studies
show that children had bear well “Humana-HA” mix
pure, it can be recommended for use in the diet of
infants with food allergy symptoms or the risk of its
development and atopic dermatitis.
Conclusions
1. Using the hypoallergenic mix “Humana-HA”
led to disappearance of atopic dermatitis signs in
almost every second child from 2 to 12 months.
2. Using partially hydrolyzed mixture “Humana-
HA” in infants with signs of atopic dermatitis
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significantly improves the flow of mild and moderate
forms.
3. Application of partial protein hydrolyzate
“Humana-HA” in the diet of infants with atopic
dermatitis reduces the content of immunoglobulin E
and interleukin-4 in serum, a minimum number of
patients which should be treatment to get one
positive result is 4.2 (95% CI 1 ,2-10, 4).
Prospects for further research
To estimate the effect of hypoallergenic blends as
to the parameters of cell’s link of children with atopy
signs.
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ÂÈÊÎÐÈÑÒÀÍÍß Ã²ÏÎÀËÅÐÃÅÍÍÎ¯ ÑÓÌ²Ø²
Ó Ä²ÒÅÉ Ç ÎÇÍÀÊÀÌÈ ÀÒÎÏ²¯.
Î.Ê. Êîëîñêîâà, Ó.². Ìàðóñèê, Î.Â. Áºëàøîâà
Ðåçþìå. Âèâ÷åíî åôåêòèâí³ñòü ã³ïîàëåðãåííèõ ìîëî÷-
íèõ ñóì³øåé ó ä³òåé ãðóäíîãî â³êó ç êë³í³÷íèìè ïðîÿâàìè
àòîï³÷íî¿ àíîìàë³¿ êîíñòèòóö³¿ ç óðàõóâàííÿì ïîêàçíèê³â
òîëåðàíòíîñò³ äî íîâî¿ ¿æ³, äèíàì³êè ïðîÿâ³â àòîï³÷íîãî äåð-
ìàòèòó, êîíöåíòðàö³¿ ³íòåðëåéê³íó-4 òà ³ìóíîãëîáóë³íó Å â
ñèðîâàòö³ êðîâ³. Âèÿâëåíî, ùî âæèâàííÿ ã³ïîàëåðãåííî¿
ñóì³ø³ «Humana –ÍÀ» ïðèçâîäèòü äî çíèêíåííÿ îçíàê àòî-
ï³÷íîãî äåðìàòèòó ïðàêòè÷íî ó êîæíî¿ äðóãî¿ äèòèíè â³êîì
â³ä 2 äî 12 ì³ñÿö³â, çíà÷íî ïîêðàùóº ïåðåá³ã ëåãêèõ ³ ñåðåä-
íüî òÿæêèõ éîãî ôîðì, ñïðèÿº íîðìàë³çàö³¿ ïðîöåñ³â òðàâ-
ëåííÿ ³ âàãîâî¿ ïðèáàâêè, çíèæóº âì³ñò ³ìóíîãëîáóë³íó Å òà
³íòåðëåéê³íó 4 â ñèðîâàòö³ êðîâ³.
Êëþ÷îâ³ ñëîâà: ä³òè, õàð÷îâà àëåðã³ÿ, àòîï³ÿ, äåðìàòèò,
÷àñòêîâ³ á³ëêîâ³ ã³äðîë³çàòè.
ÏÐÈÌÅÍÅÍÈß ÃÈÏÎÀËËÅÐÃÅÍÍÛÕ ÑÌÅÑÅÉ
Ó ÄÅÒÅÉ Ñ ÏÐÈÇÍÀÊÀÌÈ ÀÒÎÏÈÈ.
Î.Ê. Êîëîñêîâà, Ó.È. Ìàðóñûê, Î.Â. Áåëàøîâà
Ðåçþìå. Èçó÷åíà ýôôåêòèâíîñòü ãèïîàëëåðãåííûõ
ìîëî÷íûõ ñìåñåé ó äåòåé ãðóäíîãî âîçðàñòà ñ êëèíè÷åñêèìè
ïðîÿâëåíèÿìè àòîïè÷åñêîé àíîìàëèè êîíñòèòóöèè ñ ó÷åòîì
ïîêàçàòåëåé òîëåðàíòíîñòè ê íîâîé ïèùå, äèíàìèêè
ïðîÿâëåíèé àòîïè÷åñêîãî äåðìàòèòà, êîíöåíòðàöèè
èíòåðëåéêèíà-4 è èììóíîãëîáóëèíà Å â ñûâîðîòêå êðîâè.
Âûÿâëåíî, ÷òî óïîòðåáëåíèå ãèïîàëëåðãåííîé ñìåñè
«Humana-ÍÀ» ïðèâîäèò ê èñ÷åçíîâåíèþ ïðèçíàêîâ
àòîïè÷åñêîãî äåðìàòèòà ïðàêòè÷åñêè ó êàæäîãî âòîðîãî
ðåáåíêà â âîçðàñòå îò 2 äî 12 ìåñÿöåâ, çíà÷èòåëüíî óëó÷øàåò
òå÷åíèå ëåãêèõ è ñðåäíåòÿæåëûõ åãî ôîðì, ñïîñîáñòâóåò
íîðìàëèçàöèè ïðîöåññîâ ïèùåâàðåíèÿ è âåñîâîé ïðèáàâêè,
ñíèæàåò ñîäåðæàíèå èììóíîãëîáóëèíà Å è èíòåðëåéêèíà -
4 â ñûâîðîòêå êðîâè.
Êëþ÷åâûå ñëîâà: äåòè, ïèùåâàÿ àëëåðãèÿ, àòîïèÿ,
äåðìàòèò, ÷àñòè÷íûå áåëêîâûå ãèäðîëèçàòû.
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